Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Transplantation|October 8, 2005
Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipientsMarkus Pihusch, Stefan Boeck, Moritz Hamann, et al.
Breast Care (Basel, Switzerland)|November 1, 2021
PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer PatientsRudolf Napieralski, Gabriele Schricker, Gert Auer, et al.
Breast Care (Basel, Switzerland)|May 20, 2021
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute ExperienceOliver Stoetzer, Dorit Di Gioia, Rolf Dieter Issels, et al.
European Urology|August 19, 2015
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH StudyJames A Thomas, Andrea Tubaro, Neil Barber, et al.
European Urology|December 17, 2013
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
The Journal of Urology|September 16, 2014
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
The Lancet. Oncology|December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
Pageof 2